Typhoid test kit CF1002

for researchfor cancersfor genes

1. TOP2A gene amplification is often accompanied by HER-2 gene amplification in patients (about 30%-50%), which accounts for 8% of all breast cancers and has a poor prognosis. 2. CEF regimen can reduce the risk of recurrence and death in breast cancer patients with TOP2A gene amplification, which is a target of anthracyclines. 3. Patients with TOP2A gene deletion have a worse prognosis and should not be treated with anthracyclines. 4. Studies have shown that the efficacy (disease-free survival and total survival) of anthracycline chemotherapy alone (AC, cyclophosphamide + doxorubicin) in patients co-expanded with HER-2 and TOP2A was comparable to that of AC+ Herceptin. 5. Population-specific screening of anthracycline drugs before administration can reduce the side effects such as cardiotoxicity and inducing secondary leukemia.